Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

349.82 -1.20 (-0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
65 66 Next >
News headline image
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst ↗
Amgen reported a 20% year-over-year increase in second-quarter sales, reaching $8.39 billion, surpassing the $8.33 billion consensus. Guidance for 2024 includes adjusted EPS of $19.10-$20.10 and... 
Via Benzinga
News headline image
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
News headline image
AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024 ↗
AMGN stock results show that Amgen missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amgen Undercuts Its Buy Point On Mixed Second-Quarter Report ↗
Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat. 
Via Investor's Business Daily
News headline image
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Amgen's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Amgen ↗
 
Via Benzinga
News headline image
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' ↗
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... 
Via Benzinga
Topics Stocks
News headline image
Good Stocks, Strategic Options, and a 4.5% Yield: There's a Lot to Like About This Unique ETF ↗
Covered calls can generate income from an investment portfolio but can be complex. This Amplify ETF is a simple solution. 
Via The Motley Fool
Topics ETFs
News headline image
So Much For Expecting The Fed To Stick The Landing ↗
Now is not the time to be fully invested. 
Via Talk Markets
Topics Economy
News headline image
Market Whales and Their Recent Bets on AMGN Options ↗
 
Via Benzinga
News headline image
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday? ↗
U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy... 
Via Benzinga
Topics Economy Stocks
News headline image
3 Biotech Stocks That Could Have Investors Grinning Soon ↗
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
News headline image
Prediction: This Could Be Amgen's Next Massive Growth Opportunity ↗
The innovative biotech is looking for its next blockbuster. 
Via The Motley Fool
News headline image
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction ↗
Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend. 
Via Benzinga
Topics Stocks
News headline image
The Top 3 Biotech Stocks to Buy Now Summer 2024 ↗
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
News headline image
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Dividend-Paying ETFs to Secure Your Passive Income Stream ↗
Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs? 
Via InvestorPlace
Topics ETFs
News headline image
3 Fabulous Growth Stocks to Buy and Hold Forever ↗
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
Via InvestorPlace
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
News headline image
3 Stocks That Are Melting Up. Is There Room to Run? ↗
Buying stocks while they're melting up isn't without its fair share of risk. That said, these high-flyers look pretty enticing. 
Via InvestorPlace
News headline image
10 Best Dividend Growth Stocks to Buy and Hold Forever ↗
Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance. 
Via The Motley Fool
News headline image
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
News headline image
Q2 Earnings Season Scorecard, Economic Outlook And Analyst Reports For Nvidia, Meta & Others ↗
Today's Research Daily features a real-time update on the Q2 earnings season, the July Economic Outlook monthly, and new research reports on 16 major stocks, including NVIDIA, Meta, and Amgen as well... 
Via Talk Markets
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
News headline image
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data ↗
Roche released early-stage data on its oral weight-loss drug. 
Via Investor's Business Daily
News headline image
7 Dividend Stocks That Just Raised Their Payouts: July 2024 ↗
Dividend stocks have a long history of outperforming non-dividend-paying stocks, but those that increase their payout do even better. 
Via InvestorPlace
News headline image
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.